Unlike in healthy individuals, in patients with cancer, body mass did not associate with direct systemic levels of osteonectin or osteopontin, but only with the osteonectin/osteopontin ratio, which values were significantly lower in patients with pancreatic cancer compared to those of healthy controls. This evidence concerns the gene SPP1 and familial pancreatic carcinoma.